Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBR4401
- Development stage
- Unknown
- Lead developer
- Ildong Bioscience
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
BBR4401 is a parabiotic (postbiotic) derived from the heat-treated probiotic strain *Bifidobacterium breve* IDCC 4401. Developed by Ildong Bioscience, it is specifically designed for the management of moderate hypercholesterolemia by reducing LDL-cholesterol levels. Clinical data from a randomized, double-blind, placebo-controlled 12-week trial demonstrated that BBR4401 significantly lowers LDL-cholesterol, with reductions of 8.1% at low doses and 10.8% at high doses. The product has received approval from the Korean Ministry of Food and Drug Safety (KFDA) as a functional food ingredient for cholesterol health, positioning it as a non-pharmaceutical intervention for lipid management.
- Brand names
- Cholesterol Parabiotic
- Other names
- Bifidobacterium breve IDCC 4401-derived parabioticIDCC 4401IDCC4401IDCC-4401
Beyond the preview
Go deeper on BBR4401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBR4401.